[{"id":"5c1628c8-1205-4db1-a7b7-2787115fd94d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03620903","created_at":"2021-01-18T17:47:32.533Z","updated_at":"2024-07-02T16:35:04.143Z","phase":"Phase 2","brief_title":"Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia","source_id_and_acronym":"NCT03620903","lead_sponsor":"Christian Buske","biomarkers":" CD20 • CD5 • MME • FCER2","pipe":" | ","alterations":" CD5 positive","tags":["CD20 • CD5 • MME • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • bortezomib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 09/11/2019","start_date":" 09/11/2019","primary_txt":" Primary completion: 11/14/2022","primary_completion_date":" 11/14/2022","study_txt":" Completion: 09/01/2029","study_completion_date":" 09/01/2029","last_update_posted":"2024-05-13"},{"id":"68c8de81-678c-4539-bf83-7836e390592f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01788020","created_at":"2021-01-18T07:53:54.903Z","updated_at":"2024-07-02T16:35:04.236Z","phase":"Phase 3","brief_title":"Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia","source_id_and_acronym":"NCT01788020","lead_sponsor":"University of Ulm","biomarkers":" CD20 • CD5 • MME • FCER2","pipe":" | ","alterations":" CD20 positive • CD5 positive","tags":["CD20 • CD5 • MME • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • CD5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bortezomib • cyclophosphamide • dexamethasone • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 202","initiation":"Initiation: 11/01/2013","start_date":" 11/01/2013","primary_txt":" Primary completion: 11/01/2018","primary_completion_date":" 11/01/2018","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2024-05-13"},{"id":"00311e13-1aab-4ed6-8a56-3287f2ac2f03","acronym":"MAGENTA","url":"https://clinicaltrials.gov/study/NCT03081910","created_at":"2021-01-18T15:10:56.690Z","updated_at":"2024-07-02T16:35:19.728Z","phase":"Phase 1","brief_title":"Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen","source_id_and_acronym":"NCT03081910 - MAGENTA","lead_sponsor":"Baylor College of Medicine","biomarkers":" CD5","pipe":" | ","alterations":" CD5 positive","tags":["CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • fludarabine IV • MB-105 • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 11/01/2017","start_date":" 11/01/2017","primary_txt":" Primary completion: 01/15/2025","primary_completion_date":" 01/15/2025","study_txt":" Completion: 09/01/2040","study_completion_date":" 09/01/2040","last_update_posted":"2024-02-12"},{"id":"3ce69970-94bf-45cb-9554-dc5a804c3a24","acronym":"Artemis","url":"https://clinicaltrials.gov/study/NCT05832827","created_at":"2023-04-27T14:05:02.007Z","updated_at":"2025-02-25T16:18:45.546Z","phase":"Phase 2","brief_title":"First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)","source_id_and_acronym":"NCT05832827 - Artemis","lead_sponsor":"National Cancer Center, Japan","biomarkers":" KIT • CD5 • TP63","pipe":" | ","alterations":" CD5 positive","tags":["KIT • CD5 • TP63"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • paclitaxel • Lenvima (lenvatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 09/04/2023","start_date":" 09/04/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2023-10-20"},{"id":"d7c107b8-a09c-4b68-9809-e54ee7aa2819","acronym":"","url":"https://clinicaltrials.gov/study/NCT05032599","created_at":"2021-09-02T14:53:01.454Z","updated_at":"2024-07-02T16:35:56.023Z","phase":"Phase 1","brief_title":"Donor-Derived CD5 CAR T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT05032599","lead_sponsor":"Beijing Boren Hospital","biomarkers":" CD5","pipe":" | ","alterations":" CD5 positive","tags":["CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-02-08"},{"id":"51f86e2f-911c-4be2-ad25-19cd48a833c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05596266","created_at":"2022-10-27T15:58:29.771Z","updated_at":"2024-07-02T16:36:01.710Z","phase":"Phase 1","brief_title":"CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT05596266","lead_sponsor":"Xuanwu Hospital, Beijing","biomarkers":" CD5","pipe":" | ","alterations":" CD5 positive","tags":["CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD5 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/25/2022","start_date":" 10/25/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 10/25/2025","study_completion_date":" 10/25/2025","last_update_posted":"2022-10-27"},{"id":"f5570f92-10d6-4b0e-bac6-14fb8702ffbf","acronym":"","url":"https://clinicaltrials.gov/study/NCT05487495","created_at":"2022-08-04T14:55:25.822Z","updated_at":"2024-07-02T16:36:06.039Z","phase":"Phase 1","brief_title":"Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma","source_id_and_acronym":"NCT05487495","lead_sponsor":"Beijing Boren Hospital","biomarkers":" CD5","pipe":" | ","alterations":" CD5 positive","tags":["CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CD5 CAR T (CT125B)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 07/27/2022","start_date":" 07/27/2022","primary_txt":" Primary completion: 07/27/2024","primary_completion_date":" 07/27/2024","study_txt":" Completion: 07/27/2024","study_completion_date":" 07/27/2024","last_update_posted":"2022-08-04"},{"id":"f7f3b6c9-2413-4a2b-8010-74ba8820f152","acronym":"","url":"https://clinicaltrials.gov/study/NCT04767308","created_at":"2021-02-23T12:52:19.839Z","updated_at":"2024-07-02T16:36:34.227Z","phase":"Phase 1","brief_title":"Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies","source_id_and_acronym":"NCT04767308","lead_sponsor":"Huazhong University of Science and Technology","biomarkers":" ALK • CD5","pipe":" | ","alterations":" ALK negative • CD5 positive","tags":["ALK • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK negative • CD5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • RD125 • cyclophosphamide intravenous"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 03/01/2021","start_date":" 03/01/2021","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2021-02-23"},{"id":"29b53254-a1d8-4c19-8527-95390b2b9fbb","acronym":"","url":"https://clinicaltrials.gov/study/NCT00005074","created_at":"2021-01-17T22:57:05.986Z","updated_at":"2024-07-02T16:36:46.345Z","phase":"Phase 2","brief_title":"Flavopiridol in Treating Patients With Previously Untreated or Relapsed Mantle Cell Lymphoma","source_id_and_acronym":"NCT00005074","lead_sponsor":"NCIC Clinical Trials Group","biomarkers":" CD20 • CD5","pipe":" | ","alterations":" CD20 positive • CD5 positive","tags":["CD20 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • CD5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e alvocidib (DSP-2033)"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 01/24/2000","start_date":" 01/24/2000","primary_txt":" Primary completion: 02/20/2002","primary_completion_date":" 02/20/2002","study_txt":" Completion: 09/22/2008","study_completion_date":" 09/22/2008","last_update_posted":"2020-04-09"},{"id":"f5f7e9e9-4884-4e93-8627-a995d1f87bfb","acronym":"","url":"https://clinicaltrials.gov/study/NCT00562328","created_at":"2021-01-18T02:02:58.656Z","updated_at":"2024-07-02T16:36:46.382Z","phase":"Phase 2","brief_title":"Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT00562328","lead_sponsor":"Mayo Clinic","biomarkers":" CD20 • CCND1 • CD38 • CD5 • FCER2","pipe":" | ","alterations":" CD19 positive • CD38 expression • CD20 expression • CD5 positive","tags":["CD20 • CCND1 • CD38 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • CD38 expression • CD20 expression • CD5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Campath (alemtuzumab) • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 01/01/2008","start_date":" 01/01/2008","primary_txt":" Primary completion: 02/05/2010","primary_completion_date":" 02/05/2010","study_txt":" Completion: 12/18/2014","study_completion_date":" 12/18/2014","last_update_posted":"2020-04-08"}]